Chimerix, Inc. (CMRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
CMRX POWR Grades
- Quality is the dimension where CMRX ranks best; there it ranks ahead of 51.32% of US stocks.
- The strongest trend for CMRX is in Momentum, which has been heading down over the past 31 weeks.
- CMRX's current lowest rank is in the Momentum metric (where it is better than 9.33% of US stocks).
CMRX Stock Summary
- Of note is the ratio of Chimerix Inc's sales and general administrative expense to its total operating expenses; only 4.87% of US stocks have a lower such ratio.
- CMRX's price/sales ratio is 112.45; that's higher than the P/S ratio of 96.79% of US stocks.
- With a year-over-year growth in debt of 34,800%, Chimerix Inc's debt growth rate surpasses 99.81% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Chimerix Inc are EVFM, MMYT, CRMD, BEEM, and GLPG.
- CMRX's SEC filings can be seen here. And to visit Chimerix Inc's official web site, go to www.chimerix.com.
CMRX Valuation Summary
- CMRX's EV/EBIT ratio is -4.7; this is 117.6% lower than that of the median Healthcare stock.
- CMRX's price/sales ratio has moved up 99.4 over the prior 101 months.
- CMRX's price/sales ratio has moved up 99.4 over the prior 101 months.
Below are key valuation metrics over time for CMRX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CMRX | 2021-03-05 | 148.3 | 10.9 | -18.3 | -17.3 |
| CMRX | 2020-07-06 | 17.4 | 2.0 | -1.9 | -1.7 |
| CMRX | 2018-04-27 | 52.5 | 1.1 | -3.3 | -3.1 |
| CMRX | 2016-01-25 | 45.1 | 1.1 | -4.0 | -3.5 |
| CMRX | 2014-10-08 | 336.4 | 6.2 | -31.7 | -29.3 |
| CMRX | 2014-07-22 | 172.2 | 6.5 | -15.4 | -15.1 |
CMRX Price Target
For more insight on analysts targets of CMRX, see our CMRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $17.67 | Average Broker Recommendation | 1.33 (Strong Buy) |
CMRX Stock Price Chart Interactive Chart >
CMRX Price/Volume Stats
| Current price | $6.66 | 52-week high | $11.57 |
| Prev. close | $6.86 | 52-week low | $2.22 |
| Day low | $6.60 | Volume | 457,200 |
| Day high | $6.89 | Avg. volume | 922,091 |
| 50-day MA | $7.81 | Dividend yield | N/A |
| 200-day MA | $7.28 | Market Cap | 574.17M |
Chimerix, Inc. (CMRX) Company Bio
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. The company was founded in 2000 and is based in Durham, North Carolina.
Latest CMRX News From Around the Web
Below are the latest news stories about Chimerix Inc that investors may wish to consider to help them evaluate CMRX as an investment opportunity.
Chimerix to Report Second Quarter 2021 Financial Results and Provide an Operational Update on August 5, 2021DURHAM, N.C., July 29, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, August 5, 2021 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2021, and to provide an operational update. To access the live conference call, please dial (877) 354-4056 (domestic) |
Were Hedge Funds Right About Chimerix Inc (CMRX)?The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 866 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […] |
Trade Alert: The Independent Director Of Chimerix, Inc. (NASDAQ:CMRX), Fred Middleton, Has Just Spent US$78k Buying 5.1% More SharesEven if it's not a huge purchase, we think it was good to see that Fred Middleton, the Independent Director of... |
Maxim Group Sticks to Their Buy Rating for Chimerix (CMRX)Maxim Group analyst Naureen Quibria reiterated a Buy rating on Chimerix (CMRX) yesterday and set a price target of $20.00. The post Maxim Group Sticks to Their Buy Rating for Chimerix (CMRX) appeared first on Smarter Analyst . |
FDA approves Chimerix''s oral suspension smallpox antiviral, giving treatment option to dysphagic patientsFDA approves Chimerix''s oral suspension smallpox antiviral, giving treatment option to dysphagic patients ntaylor Tue, 06/08/2021 - 06:28 |
CMRX Price Returns
| 1-mo | N/A |
| 3-mo | -21.55% |
| 6-mo | -31.62% |
| 1-year | 99.40% |
| 3-year | 55.61% |
| 5-year | 58.19% |
| YTD | 37.89% |
| 2020 | 137.93% |
| 2019 | -21.01% |
| 2018 | -44.49% |
| 2017 | 0.65% |
| 2016 | -48.60% |
Continue Researching CMRX
Here are a few links from around the web to help you further your research on Chimerix Inc's stock as an investment opportunity:Chimerix Inc (CMRX) Stock Price | Nasdaq
Chimerix Inc (CMRX) Stock Quote, History and News - Yahoo Finance
Chimerix Inc (CMRX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...